Table 1

Summary of study assessments

Assessment/steps	Screening and enrolment period	Postrandomisation treatment period		Visiting period
Assessment/steps	0 hours–24 hours	1 day	2 days–1 week	90, 180, 360 days
Signed informed consent	X
Review of inclusion/exclusion criteria	X
Basic information	X
Medical history	X
Cholesterol	X	X	X
mRS	X			X
NIHSS	X	X	X
GCS	X	X	X
Routine blood test	X		X
Blood biochemistry	X		X
Coagulation	X		X
Cranial CT	X	X
CTA	X*		X*	X
MRA	X*		X*
Electrocardiography	X
DWI			X	X
DSA imaging	X*	X*	X*
Medication		X	X	X
Symptomatic intracranial haemorrhage			X
Asymptomatic intracranial haemorrhage			X
Reocclusion		X	X	X
Dead		X	X	X
Adverse event		X	X	X
Complications (undesired side-effect of medical procedure)		X	X	X
Debridement flap decompression		X	X
Clinical study completion

*CTA, MRA or DSA may be used during the screening period and the late 1 week of randomisation; CTA/MRA may be used for follow-up during postrandomisation treatment.
CTA, CT angiography; DSA, digital subtraction angiography; DWI, diffusion weight image; GCS, Glasgow Coma Scale; MRA, magnetic resonance angiography; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale Scores.